Targeted Therapies: Novel Treatment Strategies for Prostate Cancer
Author:
Mosoane Benny,Nonxuba Masibulele,Chatziioannou Aristotelis,Dlamini Zodwa
Publisher
Springer Nature Switzerland
Reference98 articles.
1. Agarwal, N., Azad, A. A., Carles, J., Fay, A. P., Matsubara, N., Heinrich, D., Szczylik, C., De Giorgi, U., Young Joung, J., Fong, P. C. C., Voog, E., Jones, R. J., Shore, N. D., Dunshee, C., Zschäbitz, S., Oldenburg, J., Lin, X., Healy, C. G., Di Santo, N., Zohren, F., & Fizazi, K. (2023). Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): A randomised, placebo-controlled, phase 3 trial. Lancet, 402, 291–303. 2. Aggarwal, R. R., Thomas, G., Youngren, J., Foye, A., Olson, S., Paris, P., Beer, T. M., Ryan, C. J., Witte, O., Evans, C. P., Gleave, M. E., Stuart, J., Alumkal, J. J., Toschi, A., Zona, N., Reiter, R. E., Lara, P., Chi, K. N., & Small, E. J. (2015). Androgen receptor (AR) amplification in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) and enzalutamide (Enz): Preliminary results from the SU2C/PCF/AACR west coast prostate cancer dream team (WCDT). Journal of Clinical Oncology, 33, 5068–5068. 3. American Cancer Society 2023. Survival rates for prostate cancer [Online]. 2023. Accessed November 08, 2023, from https://www.cancer.org/cancer/types/prostate-cancer/detection-diagnosis-staging/survival-rates.html 4. Antonarakis, E. S., Piulats, J. M., Gross-Goupil, M., Goh, J., Ojamaa, K., Hoimes, C. J., Vaishampayan, U., Berger, R., Sezer, A., Alanko, T., Wit, R. D., Li, C., Omlin, A., Procopio, G., Fukasawa, S., Tabata, K.-I., Park, S. H., Feyerabend, S., Drake, C. G., Wu, H., Qiu, P., Kim, J., Poehlein, C., & Bono, J. S. D. (2020). Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: Multicohort, open-label phase II KEYNOTE-199 study. Journal of Clinical Oncology, 38, 395–405. 5. Ashrafizadeh, M., Paskeh, M. D. A., Mirzaei, S., Gholami, M. H., Zarrabi, A., Hashemi, F., Hushmandi, K., Hashemi, M., Nabavi, N., Crea, F., Ren, J., Klionsky, D. J., Kumar, A. P., & Wang, Y. (2022). Targeting autophagy in prostate cancer: Preclinical and clinical evidence for therapeutic response. Journal of Experimental & Clinical Cancer Research, 41, 105.
|
|